Contrasting Beta Bionics (NASDAQ:BBNX) and Inogen (NASDAQ:INGN)

Beta Bionics (NASDAQ:BBNX) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares Beta Bionics and Inogen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$65.12 million	18.80	-$54.76 million	($4.37)	-6.36
Inogen	$335.70 million	0.65	-$35.89 million	($1.06)	-7.60

Inogen has higher revenue and earnings than Beta Bionics. Inogen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Beta Bionics and Inogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-87.89%	-35.72%	-20.69%
Inogen	-7.58%	-13.77%	-8.52%

Analyst Ratings

This is a summary of current recommendations for Beta Bionics and Inogen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1	3	8	1	2.69
Inogen	1	1	1	0	2.00

Beta Bionics presently has a consensus target price of $28.22, suggesting a potential upside of 1.48%. Inogen has a consensus target price of $11.00, suggesting a potential upside of 36.48%. Given Inogen’s higher probable upside, analysts clearly believe Inogen is more favorable than Beta Bionics.

Insider & Institutional Ownership

89.9% of Inogen shares are held by institutional investors. 1.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Inogen beats Beta Bionics on 9 of the 13 factors compared between the two stocks.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.